TLDR
- ARK Invest acquired approximately $24 million worth of Figma (FIG) shares following robust fourth-quarter earnings and a 6.9% increase in its stock price.
- ARK divested roughly $10.8 million in DraftKings (DKNG), extending its gradual withdrawal from the gaming platform.
- Compass Pathways (CMPS) was purchased for about $6.5 million, capitalizing on a price decline subsequent to a share offering.
- Recursion Pharmaceuticals (RXRX) was acquired for approximately $2.9 million, even though Nvidia had completely divested its stake.
- Pinterest (PINS) was sold for around $2.66 million after reporting underwhelming fourth-quarter 2025 results and a cautious forecast.
Cathie Wood’s ARK Invest executed several transactions on Thursday, February 19, 2026, according to the firm’s daily fund disclosures.
The most significant acquisition was Figma, the cloud-based design platform that recently entered the public market. ARK procured 964,342 shares, valued at approximately $24 million, primarily via its flagship ARKK exchange-traded fund.
Figma’s stock experienced a 6.9% increase on that day. The company had recently announced fourth-quarter results that surpassed both revenue and profit projections.
Figma CEO Dylan Field also countered concerns that artificial intelligence tools might negatively impact conventional software firms. He stated that Figma is leveraging AI for expansion, rather than merely for survival.
The “Make” tool enables users to input prompts that AI models from Anthropic and Google transform into application prototypes. Commencing in March, the company plans to charge for AI utilization via monthly credit allowances and a pay-per-use pricing structure.
ARK Reduces Holdings in DraftKings and Pinterest
Regarding divestments, ARK sold off 480,919 shares for about $10.8 million through its ARKK ETF. This marked the second consecutive day ARK had divested DraftKings stock.
ARK also divested 158,945 shares of Pinterest for $2.66 million. Pinterest had recently disclosed underwhelming fourth-quarter 2025 results and provided a cautious forecast for the upcoming quarter.
Investments in Mental Health and Biotech
ARK’s genomics-centric ARKG ETF acquired 781,085 shares of Compass Pathways for approximately $6.5 million. The British mental health pharmaceutical company’s stock had declined by 2.3% following the announcement of a 17.5 million share secondary offering priced at $8 per share.
ARK further acquired 780,532 shares of Recursion Pharmaceuticals for roughly $2.9 million. Recursion’s stock had surged by 5.4% on that day, rebounding from a decline triggered by reports that Nvidia had completely divested its stake in the AI drug firm during the fourth quarter.
ARK additionally purchased 28,055 shares of CRISPR Therapeutics for $1.5 million and 56,507 shares of the fintech company Klarna for slightly more than $1 million.
The firm divested 34,993 shares of Veeva Systems for $6.3 million and 31,523 shares of Twist Bioscience for $1.7 million.
Figma’s stock concluded the day with a 6.9% gain on the day of ARK’s acquisition, representing the most significant single-day movement among all equities involved in Thursday’s transactions.
